Dabigatran: Clinical correlation of drug and its dose with risk of stroke and bleeding

Dabigatran: Clinical correlation of drug and its dose with risk of stroke and bleeding

Background: Dabigatran is the first oral direct thrombin inhibitor which is endorsed by Food and Drug Administration in the prevention of embolic events in patients with nonvalvular atrial fibrillation. Suitable dose of the drug for the patient is selected based on CHA2DS2-VASc score and HAS-BLED sc...

Full description

Bibliographic Details
Main Authors: Anitta Shaji, Doody Thomas, Midhuna Saju, Suja Abraham, Ramdas Nayak
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2023-01-01
Series:Perspectives in Clinical Research
Subjects:
antiplatelet
bleeding risk
dabigatran
oral anticoagulant
thromboembolic events
Online Access:http://www.picronline.org/article.asp?issn=2229-3485;year=2023;volume=14;issue=1;spage=26;epage=31;aulast=Shaji

Internet

http://www.picronline.org/article.asp?issn=2229-3485;year=2023;volume=14;issue=1;spage=26;epage=31;aulast=Shaji

Similar Items